These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38926732)

  • 1. Intestinal mRNA expression profiles associated with mucosal healing in ustekinumab-treated Crohn's disease patients: bioinformatics analysis and prospective cohort validation.
    Li Q; Huang Z; Yang H; Tang J; Zuo T; Yang Q; Huang Z; Guo Q; Li M; Gao X; Chao K
    J Transl Med; 2024 Jun; 22(1):595. PubMed ID: 38926732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning gene expression predicting model for ustekinumab response in patients with Crohn's disease.
    He M; Li C; Tang W; Kang Y; Zuo Y; Wang Y
    Immun Inflamm Dis; 2021 Dec; 9(4):1529-1540. PubMed ID: 34469062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying hub genes in response to ustekinumab and the impact of ustekinumab treatment on fibrosis in Crohn's disease.
    Xu Y; Wang S; Ye Z; Zhang H
    Front Immunol; 2024; 15():1401733. PubMed ID: 38840917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying immune cell infiltration and effective diagnostic biomarkers in Crohn's disease by bioinformatics analysis.
    Huang R; Wang W; Chen Z; Chai J; Qi Q; Zheng H; Chen B; Wu H; Liu H
    Front Immunol; 2023; 14():1162473. PubMed ID: 37622114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
    McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
    Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting diagnostic biomarkers associated with immune infiltration in Crohn's disease based on machine learning and bioinformatics.
    Bao W; Wang L; Liu X; Li M
    Eur J Med Res; 2023 Jul; 28(1):255. PubMed ID: 37496049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease.
    Globig AM; Sommer NP; Wild K; Schardey J; Zoldan K; Thomann AK; Schulte LA; Schreiner R; Reindl W; Klaus J; Schempp CM; Hofmann M; Thimme R; Boettler T; Hasselblatt P
    Cell Mol Gastroenterol Hepatol; 2021; 11(1):1-12. PubMed ID: 32679193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of HOXD3 and UNC5C as molecular signatures in keloid based on weighted gene co-expression network analysis.
    Wang H; Zhou Z; Liu Y; Wang P; Chen L; Qi S; Xie J; Tang J
    Genomics; 2022 Jul; 114(4):110403. PubMed ID: 35709926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab Improves Active Crohn's Disease by Suppressing the T Helper 17 Pathway.
    Ihara Y; Torisu T; Miyawaki K; Umeno J; Kawasaki K; Hirano A; Fujioka S; Fuyuno Y; Matsuno Y; Sugio T; Sasaki K; Moriyama T; Akashi K; Kitazono T
    Digestion; 2021; 102(6):946-955. PubMed ID: 34350861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn's disease: a Chinese real-world study.
    Yao JY; Zhang M; Wang W; Peng X; Zhao JZ; Liu T; Li ZW; Sun HT; Hu P; Zhi M
    BMC Gastroenterol; 2021 Oct; 21(1):380. PubMed ID: 34663208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Feasibility of a Clinical Decision Support Tool for Ustekinumab to Predict Clinical Remission and Relapse in Patients With Crohn's Disease: A Multicenter Observational Study.
    Park J; Chun J; Yoon H; Cheon JH
    Inflamm Bowel Dis; 2023 Apr; 29(4):548-554. PubMed ID: 35670522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic analysis reveals the potential crosstalk genes and immune relationship between Crohn's disease and atrial fibrillation.
    Qiu X; Teng J; Wang N; Cao L; Cheng C; Su C; Dong Y; Wang F; Chen W
    J Thorac Dis; 2024 Feb; 16(2):1247-1261. PubMed ID: 38505024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.
    Rosen MJ; Karns R; Vallance JE; Bezold R; Waddell A; Collins MH; Haberman Y; Minar P; Baldassano RN; Hyams JS; Baker SS; Kellermayer R; Noe JD; Griffiths AM; Rosh JR; Crandall WV; Heyman MB; Mack DR; Kappelman MD; Markowitz J; Moulton DE; Leleiko NS; Walters TD; Kugathasan S; Wilson KT; Hogan SP; Denson LA
    Gastroenterology; 2017 May; 152(6):1345-1357.e7. PubMed ID: 28132889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six potential biomarkers in septic shock: a deep bioinformatics and prospective observational study.
    Kong C; Zhu Y; Xie X; Wu J; Qian M
    Front Immunol; 2023; 14():1184700. PubMed ID: 37359526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated multiple microarray studies by robust rank aggregation to identify immune-associated biomarkers in Crohn's disease based on three machine learning methods.
    Chen ZA; Ma HH; Wang Y; Tian H; Mi JW; Yao DM; Yang CJ
    Sci Rep; 2023 Feb; 13(1):2694. PubMed ID: 36792688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodal dynamic ultrasound approach as predictor of response in patients with Crohn's disease treated with ustekinumab.
    Ainora ME; Liguori A; Mignini I; Cintoni M; Galasso L; Laterza L; Lopetuso LR; Garcovich M; Riccardi L; Gasbarrini A; Scaldaferri F; Zocco MA
    Therap Adv Gastroenterol; 2024; 17():17562848241259289. PubMed ID: 38912296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutrophil Infiltration Characterized by Upregulation of S100A8, S100A9, S100A12 and CXCR2 Is Associated With the Co-Occurrence of Crohn's Disease and Peripheral Artery Disease.
    Yao Z; Zhang B; Niu G; Yan Z; Tong X; Zou Y; Li Y; Yang M
    Front Immunol; 2022; 13():896645. PubMed ID: 35795659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysregulation and imbalance of innate and adaptive immunity are involved in the cardiomyopathy progression.
    He B; Quan LP; Cai CY; Yu DY; Yan W; Wei QJ; Zhang Z; Huang XN; Liu L
    Front Cardiovasc Med; 2022; 9():973279. PubMed ID: 36148059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.